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Abstract
BACKGROUND
There are no consistent results between previous studies for an independent
association between non-alcoholic fatty liver disease (NAFLD) and
cardiovascular disease (CVD) events.
AIM
To determine if there is an independent association between NAFLD and CVD
events.
METHODS
In the present study, valid outcome data of 4808 subjects were available for phase
2 of our cohort study. These subjects had been followed up for seven years from
phase 1, beginning in 2009-2010 to phase 2 during 2016-2017. Simple and multiple
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Cox proportional models were used to determine the association between
NAFLD in the primary phase of the cohort and subsequent fatal and non-fatal
CVD events during follow-up.
RESULTS
The incidence of non-fatal CVD events in males with NAFLD was significantly
higher (P = 0.004) than in males without NAFLD. A positive association was
demonstrated between NAFLD and non-fatal CVD events in males (Hazard ratio
= 1.606; 95%CI: 1.166-2.212; P = 0.004) by the simple Cox proportional hazard
model, but no independent association was detected between these in the
multiple Cox models.
CONCLUSION
No independent association was detected between NAFLD and CVD. It is likely
that diabetes mellitus and age may be the principle mediators in this regard.
Key words: Non-alcoholic fatty liver disease; Cardiovascular disease; Cohort; Type 2
diabetes mellitus; Risk factor; Follow up
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: We evaluated the association between non-alcoholic fatty liver disease and the
incidence of cardiovascular disease events after seven years follow up, in a large
prospective cohort study. Based on our results, no independent association was observed
between non-alcoholic fatty liver disease and cardiovascular disease events. Diabetes
and age may play a role as potential mediators.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease
worldwide[1]. It is defined as the presence of hepatic steatosis after excluding other
causes of hepatic fat accumulation such as excessive alcohol consumption, viruses and
drug-related hepatitis[2]. The global prevalence of NAFLD was estimated to be 25.2%
in a meta-analysis of 86 studies by Younossi et al[3]. The increase in the prevalence of
NAFLD has usually followed the obesity pandemic in children and adults globally
although a considerable fraction of subjects are lean. In particular, childhood obesity
has implications for a greater risk of NAFLD later with accompanying liver-related
diseases at a much lower age threshold[1].
A number of hepatic complications from simple steato-hepatitis to cirrhosis and
hepatocellular carcinoma can be attributed to NAFLD[4]. This disease is considered to
be  a  hepatic  manifestation  of  metabolic  syndrome[5].  Thus,  in  addition  to  the
relationship with liver related diseases and its complications, this condition may be
associated  with  metabolic  co-morbidities  such  as  diabetes  mellitus  (DM)  and
dyslipidemia[6-12]. The non-liver related deaths remain far more common than liver-
related deaths[3].
We previously showed that there is a significant association between NAFLD and
10-year  cardiovascular  disease  (CVD)  risk  as  estimated  by  well  known  risk
assessment tools[13]. These tools estimate CVD risk based on a cluster of established
modifiable and non-modifiable risk factors for the development of CVD. Although
previous studies have shown a positive association between CVD events and NAFLD,
results showing an independent association between them are inconsistent[14-16]. This
study was  conducted to  determine  an  independent  association,  if  any,  between
NAFLD and CVD events.
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MATERIALS AND METHODS
Study setting and sampling frame
A comprehensive data collection was undertaken in two phases in our cohort study in
Amol. Amol, a relatively well-populated city in the central area of northern Iran, is
located 180 km from the city of Tehran. Phase 1 began in 2009-2010 and phase 2 in
2016-2017. The exact sampling frame was obtained using primary health records of
subjects from local primary health care centers in urban and rural areas. The sampling
frame, based on the primary data, comprised 16 strata according gender and the
following age group ranges within 10-90 years: 10-19, 20-29, 30-39, 40-49, 50-59, 60-69,
70-79 and 80-89. From phase 1 to the beginning of phase 2 in 2016, participants or
close family members were contacted annually to provide the outcomes related to
fatal  and  non-fatal  CVD.  The  comprehensive  evaluations  of  the  demographic,
anthropometric and laboratory variables began in early phase 2 and these participants
were actively invited to participate in this phase of the cohort study. Valid data,
following exclusions (Figure 1) was obtained, from 4808 participants, in the present
study. Figure 1 shows the study population and related inclusions and exclusions.
Outcomes
Atherosclerosis CVD (ASCVD) is defined based on the history of non-fatal acute
myocardial infarction, ischemic heart disease death and cerebrovascular accidents The
incidence of ASCVD and the number of occurrences was considered as outcomes.
Comprehensive assessment in phase 2 on the related outcomes was undertaken after
data collection from self-reporting of patients, or close family members and by direct
observation  of  valid  medical  records.  Hospital  discharge  records  and  death
certificates for fatal CVD events were evaluated. Active communications with the
locations in which the patients were hospitalized, were pursued to establish medical
record accuracy.  In all  instances,  the related outcomes provided annually by the
patient or a close family member were compared with data from valid documents,
and  modified  accordingly  in  the  case  of  inconsistent  findings.  Confirmation  of
associated outcomes was undertaken by an internist in the cohort study group.
The  diagnosis  of  NAFLD  was  by  performed  by  sonography  by  one  expert
sonographer in phase 1 of the cohort in our research center. NAFLD was defined as
hepatic steatosis in participants with no history of excess consumption of alcohol,
drug-related steatosis or viral or hereditary steatogenic hepatitis. Anthropometric
measures (height, weight) and blood pressure were measured by trained healthcare
staff.  A  calibrated  non-stretchable  meter  was  utilized  to  measure  the  height  of
shoeless participants while standing with their heels and buttocks pressed against a
wall.  Subjects  weight,  after  removal  of  excess  clothing,  was  measured  using  a
calibrated  scale  with  a  precision  of  100  g.  Blood  pressure  was  measured  with
sphygmomanometer cuffs fitted to the arm circumference of subjects after resting, for
at least 5 min in a sitting position in a quiet room. The systolic and diastolic blood
pressures were determined based on the appearance and disappearance of Korotkoff
sounds, respectively. The systolic blood pressure and diastolic blood pressure were
calculated as the average of two measurements. Whole blood samples (10 mL) were
taken from each participant using a serum separator tube, after 12 h fasting. The
samples were exposed for 1 hour at room temperature to allow for clotting, then
centrifuged rpm for 10 min and placed in 5000 cc straws with an aliquot using clean
pipette technique. The vials of serum were immediately frozen at –80 °C in a freezer.
To separate the plasma, the blood was collected in purple-topped EDTA tubes and
centrifuged (2000 rpm) at 4 °C for 20 min. Subsequently, 1.0 mL of plasma was placed
into 1.5 mL Eppendorf tubes using the clean pipette technique. Plasma samples for
each subject was immediately frozen in a –80 °C freezer. Biochemical analysis was
undergone by Auto-Analyzer  BS200 (Mindray,  Shenzhen,  China).  Pars  Azmoon
commercial diagnostic kits (Pars Azmoon Co., Tehran, Iran) included fasting blood
sugar,  high-density  lipoprotein  cholesterol,  low-density  lipoprotein  cholesterol,
triglycerides were used.
Statistical analysis
Descriptive and analytical  statistics  were used to report  the study findings.  The
incidence rate of fatal and non-fatal CVD events in participants with and without
NAFLD was obtained and compared using the two-independent group proportion
test. The simple and multiple Cox proportional models were conducted to determine
the association between NAFLD in phase 1 of the cohort and the occurrence of fatal
and non-fatal CVD events later during phases 1 and 2. The time of occurrence of fatal
and non-fatal  CVD events from 2009-2010 to 2016-2017 was considered to be the
outcome for NAFLD as the predictor. The age at onset and history of DM in phase 1
of the cohort, as the main confounding variables, was used to explain the association
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Figure 1
Figure 1  Flow diagram of phase I and phase II included and excluded participants. HCV: Hepatitis C virus; HBsAg: Hepatitis B surface antigen.
between NAFLD and CVD events.  Hazard ratios  and confidence  intervals  were
reported at  a significance level  of  0.05 for all  analyses.  The software used for all
statistical analyses was IBM SPSS version 21 (SPSS Inc., Chicago statistical software)
and STATA version 12 (STATA Corp., TX, United States).
RESULTS
According to the sampling frame stratification used in this study, male study subjects
numbered 2667 and female 2141. In these,  NAFLD prevalence,  as determined by
sonographic  data,  was  found  to  be  40.67%  (95%CI:  38.89%-42.45%)  and  43.58%
(95%CI: 41.52%-45.65%) for males and females, respectively (P = 0.0359). The basic
characteristics  of  the  study  population  of  males  and  females  without  and  with
NAFLD is shown in Table 1. The results indicate that all characteristics, except high-
density lipoprotein cholesterol, were significantly higher in participants with NAFLD
than those without NAFLD. The findings also showed that the prevalence of DM was
14.79% (95%CI: 12.77%-16.81%) within the males with NAFLD and 5.07% (95%CI:
4.04%-6.10%) in males without NAFLD (P < 0.001). On the other hand, the prevalence
of DM in females with and without NAFLD was 27.27% (95%CI: 24.47%-30.08%) and
8.06% (95%CI: 6.55%-9.57%) respectively (P < 0.001).
Figure 2 shows the incidence (%) of fatal and non-fatal CVD events in individuals
with and without NAFLD during the 7-year follow-up in males and females. In males,
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Table 1  Basic characteristics of population study in people without and with non-alcholic fatty
liver disease
Characteristics
mean ± SD
P value
Without NAFLD With NAFLD
Men (n = 2667) n = 1149 n = 1518
Age (yr) 42.02 ± 17.80 48.35 ± 14.24 < 0.001
BMI (kg/m2) 24.35 ± 3.65 29.71 ± 3.96 < 0.001
WC (cm) 84.82 ± 10.39 99.57 ± 9.65 < 0.001
DBP (mmHg) 73.76 ± 12.18 80.72 ± 12.07 < 0.001
SBP (mmHg) 114.13 ± 14.65 121.81 ± 15.71 < 0.001
FBS (mg/dL) 94.48 ± 26.74 104.45 ± 33.03 < 0.001
HOMA-IR 1.75 ± 1.42 2.90 ± 2.33 < 0.001
TG (mg/dL) 123.35 ± 76.91 173.63 ± 101.92 < 0.001
HDL (mg/dL) 45.65 ± 11.51 40.31 ± 10.94 < 0.001
LDL (mg/dL) 99.99 ± 30.30 112.27 ± 30.42 < 0.001
Women (n = 2141) n = 934 n = 1207
Age (yr) 37.88 ± 15.09 50.20 ± 12.37 < 0.001
BMI (kg/m2) 27.01 ± 4.83 33.11 ± 4.76 < 0.001
WC (cm) 84.72 ± 11.34 100.25 ± 10.48 < 0.001
DBP (mmHg) 72.32 ± 12.39 80.21 ± 12.88 < 0.001
SBP (mmHg) 110.34 ± 15.77 121.65 ± 18.03 < 0.001
FBS (mg/dL) 94.97 ± 30.36 115.22 ± 49.96 < 0.001
HOMA-IR 2.20 ± 1.62 3.43 ± 3.13 < 0.001
TG (mg/dL) 115.25 ± 67.10 173.92 ± 118.78 < 0.001
HDL (mg/dL) 48.92 ± 11.81 42.98 ± 11.68 < 0.001
LDL (mg/dL) 104.15 ± 30.62 116.51 ± 31.06 < 0.001
NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; WC: Waist circumference; DBP: Diastolic
blood pressure; SBP: Systole blood pressure; FBS: Fasting blood glucose; HOMA-IR: Homeostatic model
assessment for insulin resistance;  TG: Triglyceride;  HDL: High density lipoprotein;  LDL: Low density
lipoprotein.
the incidence of non-fatal CVD events was significantly higher in individuals with
NAFLD than those without NAFLD. Although the incidence of fatal CVD events was
higher in individuals with NAFLD than those without NAFLD, it was not statistically
significant. The incidence of fatal and non-fatal CVD events were higher in females
with  NAFLD  than  those  without  NAFLD;  however,  these  differences  were  not
statistically significant.
The Cox proportional models, used to determine the association between NAFLD
and fatal or non-fatal CVD events as related outcomes yielded the following results
(Table 2). While a positive simple association was detected between NAFLD and non-
fatal CVD events in males (Hazard ratios = 1.606; 95%CI: 1.166-2.212; P = 0.004), no
independent association was detected between them in the multiple Cox regression
models. The results show no association between NAFLD and CVD events in females
on the simple and multiple Cox proportional hazard models. Further results showed
age and diabetes mellitus have an association with fatal and non-fatal CVD events.
However, multiple cox model did not show any independent association between
diabetes mellitus and fatal CVD events in women.
DISCUSSION
We evaluated the association between NAFLD and CVD events in a prospective study
with a 7-year follow-up period. Fatal CVD events increased slightly in individuals
(both males and females) with NAFLD compared to those without NAFLD, but this
increase was not statistically significant. For non-fatal CVD events, although males
with NAFLD developed a significant slightly higher number of CVD events in the 7-
year  follow-up  compared  to  males  without  NAFLD,  this  was  not  significant  in
females. However, when we considered DM and age as potential mediators between
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Figure 2
Figure 2  The incidence of fatal and non-fatal cardiovascular disease events in individuals with and without
non-alcholic fatty liver disease during a 7-yr follow up in men and women. CVD: Cardiovascular disease; WW:
Women Without non-alcholic fatty liver disease; MN: Men with non-alcholic fatty liver disease; significant P value
showed by score.
NAFLD and CVD events, no independent relationship was detected between NAFLD
at the beginning of the study and fatal and non-fatal CVD events in the 7-year follow-
up in either males or females. Stepanova et al[17] reported an independent association
between NAFLD and CVD events in the US population after a 14.3-year follow-up,
although they found no association between CVD-related death and NAFLD, which is
in line with the findings of the current study. Several other studies have investigated
the association between NAFLD, with CVD events or outcomes. Chan et al[18] found no
association between NAFLD and prevalent Ischaemic Heart Disease (IHD) events
among patients with DM. Hamaguchi et al[19] suggested NAFLD as an independent
predictor for CVD events. Zeb et al[15] reported that NAFLD can be considered a risk
factor for non-fatal cardiac heart disease independent of traditional cardiovascular
risk factors. On the other hand, the study of Kim et al[16] found no association between
CVD death and NAFLD. Based on the evidence available to date, Targher et al[20],
suggested screening and surveillance strategies for cardiovascular diseases in patients
with NAFLD, particularly those with steatosis. They went on so far as to claim that in
many cases, people with non-alcoholic fatty liver will die of cardiovascular diseases
before they die from an advanced liver disease[20]. However, in a recent meta-analysis
of matched cohort study of 18 million European adults, Alexander et al[21]  did not
report any association between acute myocardial infarction or stroke and NAFLD,
when the related analysess were adjusted based on the established cardiovascular risk
factors. Although they emphasized on cardiovascular risk assessment in adults with
NAFLD, unlike Targher et al[20], they did not recommend strategies other than those
suggested  to  the  general  population[20,21].  Motamed et  al[13]  found an  association
between NAFLD and 10-year CVD risk as estimated by both American College of
Cardiology/American Heart Association and Framingham tools. In a more recent
study, Han et al[22], too, showed a significant association between NAFLD and CVD
risk estimated via American College of Cardiology/American Heart Association tool.
However, the risk assessment tools calculate the risks based on the data of established
risk factors[23,24]. Consequently, even assuming a very accurate prediction power for
cardiovascular events, the risks calculated by these tools cannot show an independent
relationship with such events independent of common cardiovascular risk factors.
Because there are common risk factors,  such as obesity,  diabetes mellitus,  and
insulin resistance, between nonalcoholic fatty liver and cardiovascular diseases, it is
not easy to answer the question whether the association between nonalcoholic fatty
liver  and  heart  diseases  is  caused  by  these  common  risk  factors  or  there  is  an
independent relationship between them[20]. However, as noted, our prospective study
did not confirm this relationship.
Our results emphasize that age and DM can be considered major mediators in the
development  of  non-fatal  CVD  events  in  males  with  NAFLD.  In  fact,  a  high
prevalence of DM in individuals with NAFLD and a strong association between CVD
and DM can increase the incidence of CVD events in patients with NAFLD. On the
other  hand,  the association between age with both NAFLD and CVD events  are
another cause of the increased incidence of CVD events in patients with NAFLD.
Kunutsor et al[25] showed that age has a critical role in the incidence of CVD events
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Table 2  The results of Cox proportional hazard models on fatal and non- fatal cardiovascular events as outcome, and Non-alcholic fatty
liver disease, diabetes mellitus and age as potential predictors
Sex Outcomes
Simple Cox proportional model Multiple Cox proportional model
Wald HR (95% CI) P value Wald HR (95% CI) P value
NAFLD
In men Fatal CVD events 0.963 1.345 (0.744-2.430) 0.326 0.104 0.903 (0.486-1.677) 0.747
Non-fatal CVD events 8.400 1.606 (1.166-2.212) 0.004 3.723 1.384 (0.995-1.925) 0.054
In women Fatal CVD events 1.570 1.694 (0.743-3.863) 0.210 0.002 1.178 (0.491-2.829) 0.714
Non-fatal CVD events 2.327 1.416 (0.906-2.214) 0.127 0.063 0.941 (0.584-1.516) 0.802
Diabetes mellitus
In men Fatal CVD events 37.13 6.692 (3.631-12.334) < 0.001 8.398 2.688 (1.377-5.247) 0.004
Non-fatal CVD events 30.98 2.999 (2.037-4.415) < 0.001 8.789 1.885 (1.240-2.867) < 0.001
In women Fatal CVD events 10.99 4.034 (1.769-9.201) < 0.001 2.165 1.867 (0.813-4.290) 0.141
Non-fatal CVD events 40.71 4.358 (2.773-6.850) < 0.001 14.35 2.507 (1.558-4.032) < 0.001
Age
In men Fatal CVD events 75.35 1.122 (1.094-1.152) < 0.001 62.82 1.114 (1.085-1.144) < 0.001
Non-fatal CVD events 69.12 1.043 (1.033-1.054) < 0.001 56.86 1.041 (1.030-1.052) < 0.001
In women Fatal CVD events 47.49 1.134 (1.094-1.176) < 0.001 44.91 1.133 (1.093-1.176) < 0.001
Non-fatal CVD events 63.59 1.068 (1.051-1.085) < 0.001 48.60 1.062 (1.044-1.081) < 0.001
CI: Confidence interval; CVD: Cardiovascular disease; HR: Hazard ratio; NAFLD: Non-alcholic fatty liver disease.
in patients with NAFLD in a 10.5-year follow-up. The simultaneous increase in the
incidence  of  NAFLD  and  CVD  events  could  be  expected  more  often  in  older
individuals than in younger individuals.  The association between fatty liver and
future CVD events was also attributed to dependence on insulin sensitivity by Pisto et
al[26]. The authors reported an independent relationship between fatty liver and CVD
events, following adjusting for the confounding effects of consumption of alcohol,
serum  levels  of  low-density  lipoprotein  cholesterol,  BMI  and  systolic  pressure.
However, when the confounding effects of the QUIKI index (as an index of insulin
resistance) were removed, the statistically significant relationship between fatty liver
and CVD events did not continue[26,27].
Our study showed that there is no independent association between NAFLD and
CVD events. The potential mediators of age and a history of DM were confounding
variables for the association of NAFLD and the occurrence of new cases of CVD. This
study had some limitations. One was the duration of the follow-up. The 84-month
follow-up for participants without a history of a CVD event may not be adequate to
monitor and establish full associations of CVD events between individuals with and
without NAFLD. In addition, NAFLD in this study was evaluated using sonography
rather  than liver  biopsy,  which is  regarded as  the “golden standard”.  Although
sonography is not optimal for the diagnosis of NAFLD, it is a non-invasive method
that  is  ethically  sensible  for  the  diagnosis  of  NAFLD in  research.  Additionally,
outcomes were based on objective and confirmed documentation by patients or close
family. Hence, some patients with silent CVD events in this data collection strategy
would not  have  been included in  the  study.  However,  we should  consider  that
diabetes mellitus, as an important mediator between NAFLD and CVD events in our
study, is a strong predictor for development of these silent events[28,29].
It  has  been stated that  age and DM are  two strong potential  mediators  in  the
association between NAFLD and CVD events; thus, missed cases of CVD events in
these two groups would attenuate the confounding effects of these mediators. This
issue  does  not  detract  from the  final  conclusion  that  there  was  no  independent
association between NAFLD and CVD events in the 7-year follow-up of participants
with no prior history of CVDs.
In conclusion, although we found a significant association between NAFLD and
non-fatal CVD events in males, no independent association was detected between
NAFLD and fatal  and non-fatal  CVD events in either males or females.  Diabetes
mellitus and age can be considered the principle mediators in this regard.
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ARTICLE HIGHLIGHTS
Research background
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide.
In addition to the relationship with liver related diseases and its complications, this condition
may be associated with metabolic co- morbidities such as diabetes mellitus and dyslipidemia.
Although previous studies have shown a positive association between cardiovascular disease
(CVD) events  and NAFLD, results  showing an independent  association between them are
inconsistent.
Research motivation
The main topic in this study is to determine whether non-alcoholic fatty liver can lead to an
increase in cardiovascular events independent of other potential risk factors. There is currently
no consensus in this regard in the literature. Answering this question will help us determine if
people with non-alcoholic fatty liver disease need more stringent cardiovascular interventions
than the general population.
Research objectives
This study was conducted to determine if there is an independent association between NAFLD
and CVD events.
Research methods
In this large prospective population based cohort study, valid outcome data of 4808 subjects
were analyzed. These subjects had been followed up for seven years from phase 1, beginning in
2009-2010 to phase 2 during 2016-2017. The incidence of fatal and non-fatal CVD events were
compared between people with and without NAFLD at the seven years follow up. Simple and
multiple Cox proportional models were used to determine the association between NAFLD in
the primary Phase of the cohort and subsequent fatal and non-fatal CVD events during follow-
up.
Research results
The incidence of non-fatal CVD events in males with was significantly higher than in males
without NAFLD. A positive association was demonstrated between NAFLD and non-fatal CVD
events  in  males  using  the  simple  Cox  proportional  hazard  model,  but  no  independent
association was detected between these in the multiple Cox models.
Research conclusions
Based on our results, Non-alcoholic fatty liver does not increase the risk of cardiovascular events
independent of other risk factors. Diabetes and age may play a role as potential mediators. The
presence of non-alcoholic fatty liver,  apart from other cardiovascular risk factors,  does not
increase the need for stricter interventions to prevent cardiovascular disease than the general
population.
Research perspectives
Further studies with a longer follow-up period may be needed in this area.
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